ArticleOncoTargets and therapy2013
Signal transduction molecule patterns indicating potential glioblastoma therapy approaches.
Article in OncoTargets and therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Therapeutic Strategies Targeting Anti-CD47 Therapies in Glioblastoma Multiforme: Lead or Dead End?Journal of cellular and molecular medicine · 2025Review
- The Roles of RNA-Binding Proteins in Vasculogenic Mimicry Regulation in Glioblastoma.International journal of molecular sciences · 2025Review
- Immunological and Inflammatory Biomarkers in the Prognosis, Prevention, and Treatment of Ischemic Stroke: A Review of a Decade of Advancement.International journal of molecular sciences · 2025Review
- Deciphering immune microenvironment and cell evasion mechanisms in human gliomas.Frontiers in oncology · 2023Review
- GDNF regulates lipid metabolism and glioma growth through RET/ERK/HIF‑1/SREBP‑1.International journal of oncology · 2022Article
- Fatty Acids, CD36, Thrombospondin-1, and CD47 in Glioblastoma: Together and/or Separately?International journal of molecular sciences · 2022Review
- Identification and validation of ferroptosis-related lncRNA signatures as a novel prognostic model for glioma.Frontiers in genetics · 2022Article
- Targeting FGL2 in glioma immunosuppression and malignant progression.Frontiers in oncology · 2022Review
- TRIM31 enhances chemoresistance in glioblastoma through activation of the PI3K/Akt signaling pathway.Experimental and therapeutic medicine · 2020Article
- Long non-coding RNA CASC2 targeting miR-18a suppresses glioblastoma cell growth, metastasis and EMTJournal of biosciences · 2020Article
- Long non-coding RNAs in brain tumours: Focus on recent epigenetic findings in glioma.Journal of cellular and molecular medicine · 2018Review
- miR‑141 inhibits glioma vasculogenic mimicry by controlling EphA2 expression.Molecular medicine reports · 2018Article
- LncRNA MALAT1/miR-129 axis promotes glioma tumorigenesis by targeting SOX2.Journal of cellular and molecular medicine · 2018Article
- Commentary: Pitfalls in the Neuroimaging of Glioblastoma in the Era of Antiangiogenic and Immuno/Targeted Therapy.Frontiers in neurology · 2018Article
- Commentary: Geographic Variations in the Incidence of Glioblastoma and Prognostic Factors Predictive of Overall Survival in US Adults from 2004-2013.Frontiers in aging neuroscience · 2018Article
- Inhibitory effects of a selective Jak2 inhibitor on adrenocorticotropic hormone production and proliferation of corticotroph tumor AtT20 cells.OncoTargets and therapy · 2017Article
- Different Effects of Human Umbilical Cord Mesenchymal Stem Cells on Glioblastoma Stem Cells by Direct Cell Interaction or Via Released Soluble Factors.Frontiers in cellular neuroscience · 2017Article
- Toxicological and efficacy assessment of post-transition metal (Indium) phthalocyanine for photodynamic therapy in neuroblastoma.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe expression of an array of signaling molecules, along with the assessment of real-time cell proliferation, has been performed in U87 glioma cell line and in patients' glioblastoma established cell cultures in order to provide a better understanding of cellular and molecular events involved in glioblastoma pathogenesis. Experimental therapy was performed using a phosphatidylinositol-3'-kinase (PI3K) inhibitor. PATIENTS AND
methodsxMAP technology was employed to assess expression levels of several signal transduction molecules and real-time xCELLigence platform for cell behavior.
resultsPI3K inhibition induced the most significant effects on global signaling pathways in patient-derived cell cultures, especially on members of the mitogen-activated protein-kinase family, P70S6 serine-threonine kinase, and cAMP response element-binding protein expression and further prevented tumor cell proliferation.
conclusionThe PI3K pathway might be a prime target for glioblastoma treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.